Prostate cancer biomarkers: A current perspective

Expert Review of Molecular Diagnostics

Volumn 3, Issue 4, 2003, Pages 459-470

  Kumar Sinha, Chandan ^a   Rhodes, Daniel R ^a   Yu, Jianjun ^a   Chinnaiyan, Arul ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Biomarkers; Microarray; Prostate cancer; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CYTOSKELETON PROTEIN;

CANCER DIAGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CYTOSKELETON; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MALE; ONCOGENE; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION REGULATION; VALIDATION PROCESS;

EID: 0037822213     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.4.459     Document Type: Review

References (160)

1. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J. Clin. Oncol. 21, 383-391 (2003).
2. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl. Cancer Inst. 94, 981-990 (2002).
3. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch. Pathol. Lab. Med. 119, 1122-1126 (1995). Benchmark reference on evaluation of existing biomarkers of prostate cancer.
4. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nature Rev. Cancer 2, 918-926 (2002).
5. Ross JS, Sheehan CE, Fisher HA, Kauffman RA, Dolen EM, Kallakury BV. Prognostic markers in prostate cancer. Exp. Rev. Mol. Diagn. 2, 129-142 (2002).
6. Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J. Cell. Physiol. 189, 245-256 (2001).
7. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinomas. Int. J. Cancer 103, 285-293 (2003).
8. MacGrogan D, Bookstein R. Tumour suppressor genes in prostate cancer. Semin. Cancer Biol. 8, 11-19 (1997).
9. Van Brussel JP, Mckisch GH. Prognostic factors in prostate and testis cancer. BJU Int. 83, 910-916 (1999).
10. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family: a novel panel of cancer biomarkers. Tumour Biol. 23, 185-192 (2002).
11. Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J. Urol. 169, 445-457 (2003).
12. Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin. Chem. 46, 896-900 (2000).
13. Haese A, Graefen M, Becker C et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 54, 181-186 (2003).
14. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48, 1198-1205 (2002).
15. Stephan C, Yousef GM, Scorilas A et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol. 169, 361-364 (2003).
16. Yousef GM, Scorilas A, Magklara A et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br. J. Cancer 87, 1294-1300 (2002).
17. Obiezu CV, Soosaipillai A, Jung K et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin. Chem. 48, 1232-1240 (2002).
18. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol. 169, 1138-1142 (2003).
19. Platz EA, Krithivas K, Kantoff PW, Stampfer MJ, Giovannucci E. ATAAA repeat upstream of glutathione-Stransferase P1 and prostate cancer risk. Urology 59, 159-164 (2002).
20. Singal R, van Wert J, Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 61, 4820-4826 (2001).
21. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747-1752 (2001).
22. Gsur A, Haidinger G, Hinteregger S et al. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int. J. Cancer 95, 152-155 (2001).
23. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58, 335-338 (2001).
24. Jimenez RE, Fischer AH, Petros JA, Amin MB. Glutathione S-transferase PI gene methylation: the search for a molecular marker of prostatic adenocarcinoma. Adv. Anat. Pathol. 7, 382-389 (2000).
25. Nelson WG, De Marzo AM, Deweese TL et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. NY Acad. Sci. 952, 135-144 (2001).
26. Yang G, Truong LD, Timme TL et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4, 1873-1880 (1998).
27. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59, 5719-5723 (1999).
28. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin. Cancer Res. 6, 3430-3433 (2000).
29. Nasu Y, Timme TL, Yang G et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Med. 4, 1062-1064 (1998).
30. Tahir SA, Yang G, Ebara S et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882-3885 (2001).
31. Mouraviev V, Li L, Tahir SA et al. The role of caveolin-1 in androgen insensitive prostate cancer. J. Urol. 168, 1589-1596 (2002).
32. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 27, 917-921 (1996).
33. Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45, 81-86 (1995).
34. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 57, 1086-1090 (1997).
35. Swinnen JV, Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 65, 191-198 (1998).
36. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19, 5173-5181 (2000).
37. Wang Y, Kuhajda FP, Li JN et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 167, 99-104 (2001).
38. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47, 102-110 (2001).
39. Myers RB, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J. Urol. 165, 1027-1032 (2001).
40. Verhoeven G. Androgens and increased lipogenesis in prostate cancer. Cell biologic and clinical perspectives. Verh. K Acad. Geneeskd Belg. 64, 189-195 (2002).
41. Bull JH, Ellison G, Patel A et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br. J. Cancer 84, 1512-1519 (2001).
42. Welsh JB, Sapinoso LM, Su AI et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974-5978 (2001).
43. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62, 4427-4433 (2002).
44. Furuya Y, Akimoto S, Yasuda K, Ito H. Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res. 17, 4589-4593 (1997).
45. Li JN, Gorospe M, Chrest FJ et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61, 1493-1499 (2001).
46. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA 97, 3450-3454 (2000).
47. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol. Carcinog. 5, 320-327 (1992).
48. Zhau HE, Pisters LL, Hall MC et al. Biomarkers associated with prostate cancer progression. J. Cell. Biochem. Suppl. 19, 208-216 (1994).
49. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150, 1427-1433 (1993).
50. Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front. Biosci. 5, D372-D390 (2000).
51. Ross JS, Sheehan CE, Hayner-Buchan AM et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79, 2162-2170 (1997).
52. Kallakury BV, Sheehan CE, Ambros RA et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation and HER-2/neu oncogene amplification in prostatic adenocarcinomas. J. Clin. Oncol. 16, 1302-1309 (1998).
53. Mark HF, Feldman D, Das S et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp. Mol. Pathol. 66, 170-178 (1999).
54. Signoretti S, Montironi R, Manola J et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 92, 1918-1925 (2000).
55. Savinainen KJ, Saramaki OR, Linja MJ et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. 160, 339-345 (2002).
56. Oxley JD, Winkler MH, Gillart DA, Peat DS. Her-2/neu oncogene amplification in clinically localised prostate cancer. J. Clin. Pathol. 55, 118-120 (2002).
57. Scher HI. HER2 in prostate cancer: a viable target or innocent bystander? J. Natl Cancer Inst. 92, 1866-1868 (2000). Perspective on the applicability of HER2 as a diagnostic marker of prostate cancer.
58. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16, 1743-1748 (1998).
59. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4, 811-815 (1998).
60. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291-4296 (1999).
61. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275, 1943-1947 (1997).
62. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356-362 (1997).
63. Whang YE, Wu X, Suzuki H et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad. Sci. USA 95, 5246-5250 (1998).
64. Li J, Simpson L, Takahashi M et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 58, 5667-5672 (1998).
65. Ramaswamy S, Nakamura N, Vazquez F et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 96, 2110-2115 (1999).
66. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58, 2720-2723 (1998).
67. Umbas R, Isaacs WB, Bringuier PP et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54, 3929-3933 (1994).
68. Kallakury BV, Sheehan CE, Winn-Deen E et al. Decreased expression of catenins (α and β), p120 CTN and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92, 2786-2795 (2001).
69. Umbas R, Schalken JA, Aalders TW et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52, 5104-5109 (1992).
70. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl Cancer Inst. 95 (2003). Describes the use of multiple markers in predicting recurrence of prostate cancer.
71. Ward JM, Konishi N, Ohshima M, Lamb PW, Jorcyk CL, Barrett JC. Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines. Pathol. Int. 48, 87-92 (1998).
72. Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC, Isaacs JT. Prostate cancer: biology of metastasis and its clinical implications. World J. Urol. 14, 182-189 (1996).
73. Perlino E, Lovecchio M, Vacca RA et al. Regulation of mRNA and protein levels of β1 integrin variants in human prostate carcinoma. Am. J. Pathol. 157, 1727-1734 (2000).
74. Cordon-Cardo C, Koff A, Drobnjak M et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl Cancer Inst. 90, 1284-1291 (1998).
75. Yang RM, Naitoh J, Murphy M et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol 159, 941-945 (1998).
76. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53, 3369-3373 (1993).
77. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer 56, 630-633 (1994).
78. Kallakury BV, Sheehan CE, Rhee SJ et al. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen and p34cdc2. Cancer 85, 1569-1576 (1999).
79. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182, 311-322 (2000).
80. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta KJ. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J. Natl. Cancer Inst. 92, 1941-1942 (2000).
81. Henshall SM, Quinn DI, Lee CS et al. Overexpression of the cell cycle inhibitor p 16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 7, 544-550 (2001).
82. Claudio PP, Zamparelli A, Garcia FU et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2 and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin. Cancer Res. 8, 1808-1815 (2002).
83. Wu HC, Lin CC, Chen WC, Chen HY, Tsai FJ. Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy. Eur. Urol. 43, 197-200 (2003).
84. Kristiansen G, Pilarsky C, Wissmann C et al. ALCAM/CD166 is upregulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54, 34-43 (2003).
85. Jeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J. Clin. Pathol. 56, 52-55 (2003).
86. Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. Prostate 51, 84-97 (2002).
87. Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nature Genet. 32, 321-325 (2002).
88. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51, 268-275 (2002).
89. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Overexpression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21, 8272-8281 (2002).
90. Wang Q, Sharma D, Ren Y, Fondell JD. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J. Biol. Chem. 277, 42852-42858 (2002).
91. Velasco A, Hewitt SM, Albert PS et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94, 690-699 (2002).
92. Shibata A, Garcia MI, Cheng I et al. Polymorphisms in the androgen receptor and Type II 5α-reductase genes and prostate cancer prognosis. Prostate 52, 269-278 (2002).
93. Schatzl G, Madersbacher S, Gsur A et al. Association of polymorphisms within androgen receptor, 5α-reductase and PSA genes with prostate volume, clinical parameters and endocrine status in elderly men. Prostate 52, 130-138 (2002).
94. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J. Nutr. 133, 389-392 (2003).
95. Sidiropoulos M, Chang A, Jung K, Diamandis EP. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. Br. J. Cancer 85, 393-397 (2001).
96. Rao DS, Hyun TS, Kumar PD et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J. Clin. Invest. 110, 351-360 (2002).
97. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 285, 247-256 (2002).
98. Burger MJ, Tebay MA, Keith PA et al. Expression analysis of 8-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer 100, 228-237 (2002).
99. Adsan O, Cecchini MG, Bisoffi M et al. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence? BJU Int. 90, 579-585 (2002).
100. Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94, 1449-1456 (2002).
101. Kosari F, Asmann YW, Cheville JC, Vasmatzis G. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1419-1426 (2002).
102. Ide H, Seligson DB, Memarzadeh S et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc. Natl. Acad. Sci. USA 99, 14404-14409 (2002).
103. Deyoung MP, Scheurle D, Damania H, Zylberberg C, Narayanan R. Down's syndrome-associated single minded gene as a novel tumor marker. AntiCancer Res. 22, 3149-3157 (2002).
104. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695-2698 (2002).
105. Casey G, Neville PJ, Plummer SJ et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature Genet. 32, 581-583 (2002).
106. Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M. Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ. Health Perspect. 110(Suppl. 5), 783-788 (2002).
107. Bochum S, Paiss T, Vogel W, Herkommer K, Hautmann R, Haeussler J. Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate 52, 12-19 (2002).
108. Xu J, Kalos M, Stolk JA et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 61, 1563-1568 (2001).
109. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61, 3760-3769 (2001).
110. Gronberg H, Ahman AK, Emanuelsson M, Bergh A, Damber JE, Borg A. BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 30, 299-301 (2001).
111. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest. 80, 1291-1298 (2000).
112. Aaltomaa S, Lipponen P, Viitanen J, Kankkunen JP, Ala-Opas M, Kosma VM. Prognostic value of CD44 standard, variant isoforms 3 and 6 and catenin expression in local prostate cancer treated by radical prostatectomy. Eur. Urol. 38, 555-562 (2000).
113. Verkaik NS, Trapman J, Romijn JC, Van der Kwast TH, Van Steenbrugge GJ. Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int. J. Cancer 80, 439-443 (1999).
114. Reiter RE, Sato I, Thomas G et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 27, 95-103 (2000).
115. Mita K, Nakahara M, Usui T. Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int. J. Urol. 7, 321-329 (2000).
116. Gsur A, Bernhofer G, Hinteregger S et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer 87, 434-437 (2000).
117. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP III. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 89, 412-423 (2000).
118. Hubert RS, Vivanco I, Chen E et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl Acad. Sci. USA 96, 14523-14528 (1999).
119. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
120. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 60, 1677-1682 (2000).
121. Rubin MA, Zhou M, Dhanasekaran SM et al. α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662-1670 (2002). Described clinical applicability of αmethylacyl-CoA racemase, a molecule discovered by microarray profiling.
122. Luo J, Zha S, Gage WR et al. α-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62, 2220-2226 (2002).
123. Jiang Z, Wu CL, Woda BA et al. P504S/α-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am. J. Surg. Pathol. 26, 1169-1174 (2002).
124. Yang XJ, Wu CL, Woda BA et al. Expression of α-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am. J. Surg. Pathol. 26, 921-925 (2002).
125. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. α-methylacyl-CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am. J. Surg. Pathol. 26, 926-931 (2002).
126. Kuefer R, Varamba]ly S, Zhou M et al. α-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am. J. Pathol. 161, 841-848 (2002).
127. Zheng SL, Chang BL, Faith DA et al. Sequence variants of α-methylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res. 62, 6485-6488 (2002).
128. LaTulippe E, Satagopan J, Smith A et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
129. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
130. Zetter BR, Banyard J. Cancer: the silence of the genes. Nature 419, 572-573 (2002).
131. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor: a marker or mover of metastatic prostate cancer? Cancer Cell 2, 349-350 (2002).
132. Magee JA, Araki T, Patil S et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61, 5692-5696 (2001).
133. Luo J, Duggan DJ, Chen Y et al. Human prostate cancer and benign hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61, 4683-4688 (2001).
134. Ernst T, Hergenhahn M, Kenzelmann M et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am. J. Pathol. 160, 2169-2180 (2002).
135. Stamey TA, Warrington JA, Caldwell MC etal. Molecular genetic profiling of Gleason Grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol. 166, 2171-2177 (2001).
136. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 62, 6812-6816 (2002).
137. Srivastava M, Bubendorf L, Nolan L et al. ANX7 as a biomaker in prostate and breast cancer progression. Dis. Markers 17, 115-120 (2001).
138. Srivastava M, Bubendorf L, Srikantan V et al. ANX7, a candidate tumor suppressor gene for prostate cancer. Proc. Natl Acad. Sci. USA 98, 4575-4580 (2001).
139. Paweletz CP, Ornstein DK, Roth MJ et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 60, 6293-6297 (2000).
140. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin protein family is associated with prostate cancer progression. Am. J. Pathol. 162, 255-261 (2003).
141. Luo JH, Yu YE, Cieply K et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35 (2002).
142. Singh D, Febbo PG, Ross K et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002). Describes application of microarray-derived data to establish clinical behavior of prostate cancer.
143. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nature Genet. 32(Suppl.), 533-540 (2002).
144. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94, 1576-1578 (2002). Introduced the idea of using serum proteomic patterns for diagnostics.
145. Qu Y, Adam BL, Yasui Y et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48, 1835-1843 (2002).
146. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614 (2002).
147. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50, 54-63 (2002).
148. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1, 1264-1270 (2001).
149. Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235-2242 (2000).
150. Mintz PJ, Kim J, Do KA et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nature Biotechnol. 21, 57-63 (2003).
151. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000). Hallmark review on cancer biology.
152. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
153. Alers JC, Rochat J, Krijtenburg PJ et al. Identification of genetic markers for prostatic cancer progression. Lab. Invest. 80, 931-942 (2000).
154. Cher ML, Bova GS, Moore DH et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56, 3091-3102 (1996).
155. Qian J, Bostwick DG, Takahashi S et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 55, 5408-5414 (1995).
156. Visakorpi T, Kallioniemi AH, Syvanen AC et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55, 342-347 (1995).
157. Bova GS, Isaacs WB. Review of allelic loss and gain in prostate cancer. World J. Urol. 14, 338-346 (1996).
158. Zitzelsberger H, Engert D, Walch A et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br. J. Cancer 84, 202-208 (2001).
159. Weinberg RA. One renegade cell: how cancer begins (Edition 1). Basic Books (Perseus Books Group), New York, USA (1999). Website
160. American Cancer Society Facts and Figures Available at: www.cancer.org (Viewed June 2003)